Idoxuridine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Idoxuridine
- Pharmacist Assessment Report
- Idoxuridine: From Herpes Simplex Virus Keratitis to Vulvovaginal Candidiasis
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Idoxuridine: From Herpes Simplex Virus Keratitis to Vulvovaginal Candidiasis
One-Sentence Summary
Idoxuridine is a thymidine analog antiviral, originally used as an eye drop for herpes simplex virus keratitis. The TxGNN model predicts it may be effective for vulvovaginal candidiasis, but no clinical trials and no publications currently support this prediction. The most mechanistically plausible candidate among the top predictions is herpetic vulvovaginitis, which also has no direct trials or literature.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Herpes simplex virus keratitis |
| Predicted New Indication | Vulvovaginal candidiasis |
| TxGNN Prediction Score | 0.9992 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data |
| Number of Listed Products | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, idoxuridine is a thymidine analog that inhibits viral DNA synthesis, and its efficacy in herpes simplex virus keratitis is established. Mechanistically it is relevant mainly to DNA viruses.
For the top-ranked prediction, vulvovaginal candidiasis, there is no plausible mechanistic link. Candida is a fungus and does not rely on the viral thymidine kinase-dependent replication that this drug targets. The high score is a computational result only.
Several other predicted indications also lack a rationale. Trichomonal vulvovaginitis (a protozoan infection), bacterial vaginosis (a polymicrobial dysbiosis), postmenopausal atrophic vaginitis (driven by estrogen deficiency) and nonspecific vaginal discharge have no mechanistic link to an antiviral nucleoside analog.
The most coherent candidate is herpetic vulvovaginitis (score 0.9959). Idoxuridine inhibits HSV DNA replication, so activity against genital HSV is biologically reasonable. However, acyclovir and valacyclovir have far stronger evidence and a better safety profile, so repurposing idoxuridine would offer little clinical advantage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No literature was retrieved for vulvovaginal candidiasis. The literature below was retrieved for related female genital tract indications (vaginitis, vulvitis, vulvovaginitis). It is indirect and old, and no abstracts were available.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 14275292 | 1965 | Review / clinical report | Obstetrics and Gynecology | Herpes simplex infection in the female genital tract. Indirect relevance to herpetic vulvovaginitis, vulvitis and vulvovaginitis. |
| 7814938 | 1994 | Other (likely clinical series) | Nihon Sanka Fujinka Gakkai Zasshi | Topical idoxuridine and acrarubicin for genital condyloma acuminatum and vaginal intraepithelial neoplasia (VAIN). Indirect relevance to vaginitis. |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Registration No. 186442 | Ridinox 0.1% Eye Drop (Bell Pharma Pvt Ltd) | Packet of 10 ml eye drop | Not specified in the data compiled for this report |
The only marketed form is an ophthalmic eye drop. A formulation suitable for vaginal or vulvar use has not been identified, and route compatibility for the predicted indications has not been assessed.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication is supported only by a computational score. There are no clinical trials, and the sole literature is indirect and decades old. For vulvovaginal candidiasis there is no plausible mechanism. The one biologically coherent option, herpetic vulvovaginitis, is already well served by modern systemic antivirals. The only marketed product is an eye drop.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap that prevents safety screening)
- Detailed mechanism of action data
- If pursuing herpetic vulvovaginitis as a research question, a targeted literature review and comparison against acyclovir and valacyclovir
- Assessment of formulation and route feasibility for genital use, since only an ophthalmic product is registered in India
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.